The P.1 strain contains mutations E484K, N501Y, and K417T, which enhance the virus’s affinity with ACE2 and enable evasion of neutralizing antibodies in convalescent plasma from early COVID-19 patients (14). This evidence concerns the gene ACE2 and COVID-19.